The pharmaceutical economics of child psychiatric drug treatment

Current Pharmaceutical Design

Volumn 16, Issue 22, 2010, Pages 2443-2461

  Schlander, Michael ^a,b,c  

^a Institute for Innovation and Valuation in Health Care (InnoValHC)   (Germany)

^b UNIVERSITY OF HEIDELBERG   (Germany)

^c University of Applied Economic Sciences LudwigshafenLudwigshafen am Rhein   (Germany)

Author keywords

Attention deficit hyperactivity disorder (ADHD); Cost benefit analysis; Cost effectiveness analysis; Cost utility analysis; Depression; Economic evaluation; Health technology assessment; Pharmacoeconomics; Quality adjusted life year (QALY)

Indexed keywords

ANTIDEPRESSANT AGENT; ATOMOXETINE; LISDEXAMFETAMINE; METHYLPHENIDATE; MPH MR08; MPH MR12; PSYCHOSTIMULANT AGENT; UNCLASSIFIED DRUG;

ADOLESCENT; ANXIETY; ATTENTION DEFICIT DISORDER; CHILD; COST EFFECTIVENESS ANALYSIS; DEPRESSION; DRUG EFFICACY; HEALTH ECONOMICS; HUMAN; MAJOR DEPRESSION; PHARMACOECONOMICS; PRIORITY JOURNAL; PSYCHIATRIC TREATMENT; QUALITY ADJUSTED LIFE YEAR; REVIEW;

ADOLESCENT; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; CENTRAL NERVOUS SYSTEM STIMULANTS; CHILD; CLINICAL TRIALS AS TOPIC; COST-BENEFIT ANALYSIS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY; ECONOMICS, PHARMACEUTICAL; HUMANS; MODELS, ECONOMIC; MODELS, STATISTICAL; QUALITY-ADJUSTED LIFE YEARS; TREATMENT OUTCOME;

EID: 77955600818     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161210791959917     Document Type: Review

References (247)

1. Romeo R, Byford S, Knapp M. Annotation: economic evaluations of child and adolescent mental health interventions: a systematic review. J Child Psychol Psychiatry 2005; 46 (9): 919-30.
2. Brent RJ. Cost-benefit analysis and health care evaluations. Cheltenham. Edward Elgar 2003.
3. Gold MR, Siegel JE, Russell LB, et al. Cost-effectiveness in health and medicine. New York, NY: Oxford University Press 1996.
4. rd ed. Oxford: Oxford University Press 2005.
5. Gilmore A, Milne R. Methylphenidate in children with hyperactivity: review and cost-utility analysis. Pharmacoepidemiol Drug Saf 2001; 10: 85-94.
6. Health Economics Evaluations Database (HEED). Available at www.ohe-heed.com/
7. Schlander M. Health technology assessments by the National Institute for Health and Clinical Excellence. A qualitative study. New York, NY: Springer 2007.
8. Sorenson C, Drummond M, Kanavos P. Ensuring value for money in health care. The role of health technology assessment in the European Union. Copenhagen: WHO Regional Office for Europe 2008.
9. Schlander M. Impact of attention-deficit/hyperactivity disorder (ADHD) on prescription drug spending for children and adolescents: increasing relevance of health economic evidence. Child Adolesc Psychiatr Mental Health 2007; 1 (1): 13.
10. Costello EJ, Egger H, Angold A. 10-year research update review: the epidemiology of child and adolescent psychiatric disorders: methods and public health burden. J Am Acad Child Adolesc Psychiatry 2005; 44 (10): 972-86.
11. Belfer ML. Child and adolescent mental disorders: the magnitude of the problem across the globe. J Child Psychol Psychiatry 2008; 49 (3): 226-36.
12. Anders TF. Children: our most valuable resource. J Am Acad Child Adolesc Psychiatry 2006; 45 (1): 1-5.
13. Clavenna A, Bonati M. Drug prescriptions to outpatient children: a review of the literature. Eur J Clin Pharmacol 2009; 65: 749-55.
14. Vitiello B. An international perspective on pediatric psychopharmacology. Int Rev Psychiatry 2008; 20 (2): 121-6.
15. Scheffler RM, Hinshaw SP, Modrek S, et al. The global market for ADHD medications. Health Affairs 2007; 26: 450-7.
16. Zito JM, Tobi H, de Jong-van den Berg LTW, et al. Antidepressant prevalence for youths: a multi-national comparison. Pharmacoepidemiol Drug Saf 2006; 15 (11): 793-8.
17. Zito JM, Safer DJ, de Jong-van den Berg LTW, et al. A threecountry comparison of psychotropic medication prevalence in youth. Child Adolesc Psychiatr Mental Health 2008; 2: 26.
18. Fegert J, Kölch M, Zito JM, et al. Antidepressant use in children and adolescents in Germany. J Child Adolesc PsychoPharmacol 2006; 16: 197-206.
19. Sawyer MG, Arney PA, Baghurst PA, et al. The mental health of young people in Australia: key findings from the child and adolescent component of the national survey of mental health and wellbeing. Aust N Z J Psychiatry 2001; 35: 806-14.
20. Waddell C, Offord DR, Shepherd CA, et al. Child psychiatric epidemiology and Canadian public policy-making: the state of the science and the art of the possible. Canadian J Psychiatry 2002; 47: 825-32.
21. Aras S, Varol Tas F, Unlu G. Medication prescribing practices in a child and adolescent psychiatry outpatient clinic. Child: Care Health Develop 2006; 33 (4): 482-90.
22. Rappley MD. Attention deficit-hyperactivity disorder. New Eng J Med 2005; 352 (2): 165-73.
23. Polanczyk G, Jensen P. Epidemiologic considerations in attention deficit hyperactivity disorder: a review and update. Child Adolesc Psychiatr Clin North Am 2008; 17 /2): 245-60.
24. Leibson CL, Long KH. Economic implications of attentiondeficit/hyperactivity disorder for healthcare systems. Pharmacoeconomics 2003; 21 (17): 1239-62.
25. Matza LS, Paramore C, Prasad M. A review of the economic burden of ADHD. Cost Eff Resour Alloc 2005; 3: 5.
26. Swensen AR, Birnbaum HG, Secnik K, et al. Attentiondeficit/hyperactivity disorder: increased costs for patients and their families. J Am Acad Child Adolesc Psychiatry 2003; 42 (12): 1415-23.
27. Barkley RA. Driving impairments in teens and adults with attention-deficit/ hyperactivity disorder. Psychiatr Clin North Am 2004; 27 (2): 233-60.
28. Lam LT. Attention deficit disorder and hospitalization due to injury among older adolescents in New South Wales, Australia. J Attention Disord 2002; 6 (2): 77-82.
29. Hoare P, Beattie T. Children with attention deficit hyperactivity disorder and attendance at hospital. European J Emerg Med 2003; 10 (2): 98-100.
30. Swensen A, Birnbaum HG, Ben Hamadi R, et al. Incidence and costs of accidents among attention-deficit/hyperactivity disorder patients. J Adolesc Health 2004; 35 (4): 346.e1-9.
31. Wilens TE, Biederman J. Alcohol, drugs, and attentiondeficit/hyperactivity disorder: a model for the study of addictions in youth. J PsychoPharmacol 2006; 20 (4): 580-8.
32. Rasmussen P, Gillberg C. Natural outcome of ADHD with developmental coordination disorder at age 22 years: a controlled, longitudinal, community-based study. J Am Acad Child Adolesc Psychiatry 2000; 39 (11): 1424-31.
33. Mannuzza S, Klein RG, Abikoff H, et al. Significance of childhood conduct problems to later development of conduct disorder among children with ADHD: a prospective follow-up study. J Abnorm Child Psychol 2004; 32 (5): 565-73.
34. Thapar A, van den Bree M, Fowler T, et al. Predictors of antisocial behaviour in children with attention deficit hyperactivity disorder. Eur Child Adolesc Psychiatry 2006; 15 (2): 118-25.
35. Siponmaa L, Kristiansson M, Jonson C, et al. Juvenile and young adult mentally disordered offenders: the role of child neuropsychiatric disorders. J Am Acad Psychiatr Law 2001; 29 (4): 420-6.
36. Rösler M, Retz W, Retz-Junginger P, et al. Prevalence of attentiondeficit/ hyperactivity disorder (ADHD) and comorbid disorders in young male prison inmates. Eur Arch Psychiatr Clin Neurosci 2004; 254 (6): 365-71.
37. Johansson P, Kerr M, Andershed H. Linking adult psychopathy with childhood hyperactivity-impulsivity-attention problems and conduct problems through retrospective self-reports. J Person Disord 2005; 19 (1): 94-101.
38. Sourander A, Elonheimo H, Niemela S, et al. Childhood predictors of male criminality: a prospective population-based follow-up study from age 8 to late adolescence. J Am Acad Child Adolesc Psychiatry 2006; 45 (5): 578-86.
39. Mannuzza S, Klein RG, Bessler A, et al. Educational and occupational outcome of hyperactive boys grown up. J Am Acad Child Adolesc Psychiatry 1997; 36 (9): 1222-7.
40. Barkley RA. Major life activity and health outcomes associated with attention-deficit/ hyperactivity disorder. J Clin Psychiatry 2002; 63 (Suppl 12): 10-15.
41. Murphy KR, Barkley RA, Bush T. Young adults with attention deficit hyperactivity disorder: subtype differences in comorbidity, educational, and clinical history. J Nerv Mental Disord 2002; 190 (3): 147-57.
42. Furness SR, Kavale KA. Impact of ADHD on school systems. In: Jensen PS, Cooper JR, Eds. Attention deficit hyperactivity disorder. Kingston, NJ: Civic Research Institute 2002; pp. 24-1-24-30.
43. Pelham WE, Foster EM, Robb JA. The economic impact of attention-deficit/hyperactivity disorder in children and adolescents. J Pediatr Psychol 2007; 32 (6): 711-27.
44. Knapp M, Scott S, Favis J. The cost of antisocial behavior in younger children. Clin Child Psychol Psychiatry 1999; 4: 457-73.
45. Schlander M, Trott GE, Schwarz O. The health economics of attention-deficit/hyperactivity disorder in Germany - Part 1: health care utilization and cost of illness. Nervenarzt 2010; 81 (3): 289-300.
46. Wehmeier PM, Schacht A, Rothenberger A. Change in the direct cost of treatment for children and adolescents with hyperkinetic disorder in Germany over a period of four years. Child Adolesc Psychiatr Mental Health 2009; 3 (1): 3.
47. Gillberg C, Gillberg IC, Rasmussen P, et al. Co-existing disorders in ADHD - implications for diagnosis and intervention. Eur Child Adolesc Psychiatry 2004; 13 (Suppl 1): 80-92.
48. Steinhausen H-C, Nøvik TS, Baldursson G, et al. Co-existing psychiatric problems in ADHD in the ADORE cohort. Eur Child Adolesc Psychiatry 2006; 15 (Suppl 1): 4-14.
49. Schlander M, Schwarz O, Trott GE, et al. Comorbidity profiles of children and adolescents with ADHD - an analysis based on administrative data from Nordbaden, Germany. J Mental Health Policy Econ 2007; 10 (Suppl 1): S39.
50. Spencer TJ, Biederman J, Mick E. Attention-deficit/hyperactivity disorder: diagnosis, lifespan, comorbidities, and neurobiology. J Pediatr Psychol 2007; 32 (6): 631-42.
51. Jensen PS, Martin D, Cantwell DP. Comorbidity in ADHD: implications for research, practice, and DSM-IV. J Am Acad Child Adolesc Psychiatry 1997; 36: 1065-79.
52. Chan E, Zhan C, Homer CJ. Health care use and costs for children with attention-deficit/hyperactivity disorder. Arch Pediatr Adolesc Med 2002; 156: 504-11.
53. Guevara J, Lozano P, Wickizer T, et al. Utilization and cost of health services for children with attention-deficit/hyperactivity disorder. Pediatrics 2001; 108: 71-8.
54. Burd L, Klug MG, Coumbe MJ, et al. The attention-deficit hyperactivity disorder paradox: 2. Phenotypic variability in prevalence and cost of comorbidity. J Child Neurol 2003; 18: 653-60.
55. Schlander M, Schwarz O, Trott GE, et al. Health service expenditures for children and adolescents with and without attentiondeficit/ hyperactivity disorder (ADHD) in Germany - impact of coexisting conditions. Value Health 2008; 11 (6): A340.
56. Spencer TJ. ADHD and comorbidity in childhood. J Clin Psychiatry 2006; 67 (Suppl 8): 27-31.
57. Jensen PS, Hinshaw SP, Kraemer HC, et al. ADHD comorbidity findings from the MTA Study: comparing comorbid subgroups. J Am Acad Child Adolesc Psychiatry 2001; 40 (2): 147-58.
58. Ollendick TH, Jarrett MA, Grills-Taquechel AE, et al. Comorbidity as a predictor and moderator of treatment outcome in youth with anxiety, affective, attention deficit/hyperactivity disorder, and oppositional/ defiant disorders. Clin Psychol Rev 2008; 28: 1447-71.
59. th ed. Washington, DC: Am Psychiatric Association 1994.
60. th ed. Geneva, Switzerland: The World Health Organization 1992.
61. Wolraich ML, Hannah JN, Baumgaertel A, et al. Examination of DSM-IV criteria for attention deficit/hyperactivity disorder in a county-wide sample. J Develop Behav Pediatr 1998; 19: 162-8.
62. Tripp G, Luk SL, Schaughency EA, et al. DSM-IV and ICD-10: a comparison of the correlates of ADHD and hyperkinetic disorder. J Am Acad Child Adolesc Psychiatry 1999; 38 (2): 156-64.
63. American Psychiatric Association (APA). Handbook of psychiatric measures. Washington, DC: APA 2000.
64. Collett BR, Ohan JL, Myers KM. Ten-year review of rating scales. V. Scales assessing attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 2003; 42 (9): 1015-37.
65. Drummond M, Pang F. Transferability of economic evaluation results. In: Drummond M, McGuire A, Eds. Economic evaluation in health care - merging theory with practice. Oxford: Oxford University Press 2001; pp. 256-76.
66. Reinhold T, Brueggenjuergen B, Rosenfeld S, et al. Economic analysis based on multinational studies - methods for adapting findings to national contexts. J Public Health (published online February 05, 2010).
67. Taylor E, Döpfner M, Sergeant J, et al. European clinical guidelines for hyperkinetic disorder - first upgrade. Eur Child Adolesc Psychiatry 2004; 13 (Suppl 1): 17-30.
68. Remschmidt H, Global ADHD Working Group. Global consensus on ADHD/HKD. Eur Child Adolesc Psychiatry 2005; 14 (3): 127-37.
69. Banaschewski T, Coghill D, Santosh P, et al. Long-acting medications for the hyperkinetic disorders. A systematic review and European treatment guideline. Eur Child Adolesc Psychiatry 2006; 15 (8): 476-95.
70. Brown RT, Amler RW, Freeman WS, et al. Treatment of attentiondeficit/ hyperactivity disorder; overview of the evidence. Pediatrics 2005; 115 (6): e749-57.
71. Pliszka S. AACAP Work Group on Quality Issues. Practice parameter for the assessment and treatment of children and adolescents with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 2007; 46 (7): 894-921.
72. Knapp MRJ. Economic evaluation and interventions for children and adolescents with mental health problems. J Child Psychol Psychiatry 1997; 38: 3-26.
73. Volkow ND, Wang G, Fowler JS, et al. Therapeutic doses of oral methylphenidate significantly increase extracellular dopamine in the human brain. J Neurosci 2001; 21 (2): RC121.
74. Wilens TE. Effects of methylphenidate on the catecholaminergic system in attention-deficit/hyperactivity disorder. J Clin Psycho-Pharmacol 2008; 3 (suppl 2): S46-53.
75. Heal DJ, Cheetham SC, Smith SL. The neuropharmacology of ADHD drugs in vivo: insights on efficacy and safety. Neuropharmacology 2009; 57 (7-8): 608-18.
76. Hogan V. Pemoline (Cylert): market withdrawal. Canadian Med Assoc J (CMAJ) 2000; 162 (1): 106.
77. Wilens TE, Dodson W. A clinical perspective of attentiondeficit/hyperactivity disorder into adulthood. J Clin Psychiatry 2004; 65 (10): 1301-13.
78. Daughton JM, Kratochvil CJ. Review of ADHD pharmacotherapies: advantages, disadvantages, and clinical pearls. J Am Acad Child Adolesc Psychiatry 2009; 48 (3): 240-8.
79. Garnock-Jones KP, Keating GM. Atomoxetine: a review of its use in attention-deficit/hyperactivity disorder in children and adolescents. Paediatr Drugs 2009; 11 (3): 203-26.
80. Michelson D, Allen AJ, Busner J, et al. Once-daily atomoxetine treatment for children and adolescents with attention deficit hyperactivity disorder: a randomized, placebo-controlled study. Am J Psychiatry 2002; 159 (11): 1896-901.
81. Gafni A, Birch S. Incremental cost-effectiveness ratios (ICERs): the silence of the lambda. Soc Sci Med 2006; 62: 2091-100.
82. Consumer Reports. best buy drugs: evaluating prescriptions drugs used to treat attention deficit hyperactivity disorder (ADHD): comparing effectiveness, safety, and price. Available online at www.consumerreports.org/health/best-buy-drugs/index.htm. [Last accessed December 30, 2009].
83. Gelbe Liste. Available online at www.gelbe-liste.de. Last accessed December 30, 2009.
84. British National Formulary No. 58, September 2009. Available online at www.bnf.org. [Last accessed December 30, 2009].
85. Dundar Y, Dodd S, Dickson R, et al. Comparison of conference abstracts and presentations with full-text articles in the health technology assessments of rapidly evolving technologies. Health Technol Assess 1996; 10 (5): 1-45.
86. U.S. Congress, Office of Technology Assessment. Health care technology and its assessment in eight countries, OTA-BP-H-140 Washington, DC: U.S. Government Printing Office 1995.
87. Giacomini M. One of these things is not like the others: the idea of precedence in health technology assessment and coverage decisions. Milbank Quart 2005; 83 (2): 193-223.
88. Miller A, Lee SK, Raina P, et al. A review of therapies for attention- deficit/hyperactivity disorder. Ottawa, ON: Canadian Coordinating Office for Health Technology Assessment (CCOHTA) 1998.
89. Zupancic JAF, Miller A, Raina P, et al. Economic evaluation of pharmaceutical and psychological/behavioural therapies for attention-deficit/hyperactivity disorder. In: Miller A, Lee SK, Rain P, et al. Eds. A review of therapies for attention-deficit/hyperactivity disorder. Ottawa, ON: Canadian Coordinating Office for Health Technology Assessment (CCOHTA) 1998.
90. Klassen A, Miller A, Raina P, et al. Attention-deficit hyperactivity disorder in children and youth: a quantitative systematic review of the efficacy of different management strategies. Canadian J Psychiatry 1999; 44 (10): 1007-16.
91. Firestone P, Crowe D, Goodman JT, et al. Vicissitudes of followup studies: differential effects of parent training and stimulant medication with hyperactives. Am J Orthopsychiatry 1986; 56 (2): 184-94.
92. Miller AR, Lalonde CE, McGrail KM. Children's persistence with methylphenidate therapy: a population-based study. Canadian J Psychiatry 2004; 49 (11): 761-8.
93. Firestone P. Factors associated with children's adherence to stimulant medication. Am J Orthopsychiatry 1982; 52 (3): 447-57.
94. Shukla VP, Otten N. Assessment of attention deficit/hyperactivity disorder therapy: a Canadian perspective. Ottawa, ON: Canadian Coordinating Office for Health Technology Assessment (CCOHTA) 1999.
95. Canadian Agency for Drugs and Technologies in Health (CADTH). Long versus short acting drugs for attention deficit hyperactivity disorder. Project number 487. Available online at http: //www.acmts.ca/index.php/en/hta/projects?&filter_field=2. [Last accessed January 30, 2010].
96. Lord J, Paisley S. The clinical effectiveness and cost-effectiveness of methylphenidate for hyperactivity in childhood. London: National Institute for Clinical Excellence (NICE). Version 2, 2000.
97. Jadad AR, Boyle M, Cunningham C, et al. Treatment of attentiondeficit/hyperactivity disorder. Evidence Report/Technology Assessment No 11 (prepared by McMaster University under contract no 290-97-0017). AHRQ Publication No 00-E005. Rockville, MD: Agency for Healthcare Research and Quality (AHRQ) 1999.
98. Gilmore A, Best L, Milne R. Methylphenidate in children with hyperactivity. DEC Report No 78. Southampton: Wessex Institute for Health Research and Development 1998.
99. MTA Cooperative Group. A 14-month randomized clinical trial of treatment strategies for attention-deficit/hyperactivity disorder. Arch Gen Psychiatry 1999; 56: 1073-86.
100. MTA Cooperative Group. Moderators and mediators of treatment response for children with attention-deficit/hyperactivity disorder: the multimodal treatment study of children with attentiondeficit/hyperactivity disorder. Arch Gener Psychiatry 1999; 56: 1088-96.
101. National Institute for Clinical Excellence (NICE). Health Technology Appraisal: Methylphenidate, atomoxetine and dexamfetamine for attention deficit hyperactivity disorder (ADHD) in children and adolescents including review of existing guidance number 13 (Guidance on the Use of Methylphenidate [Ritalin, Equasym] for Attention Deficit/Hyperactivity Disorder [ADHD] in childhood) - Scope. London: NICE 2003.
102. National Institute for Clinical Excellence (NICE). Special health authority tenth wave work programme: attention deficit hyperactivity disorder. Remit. London: NICE 2004.
103. King S, Riemsma R, Hodges Z, et al. Technology Assessment Report for the HTA Programme: Methylphenidate, dexamfetamine and atomoxetine for the treatment of attention deficit hyperactivity disorder. Final version. London: NICE 2004.
104. King S, Griffin S, Hodges Z, et al. A systematic review of the clinical and cost-effectiveness of methylphenidate hydrochloride, dexamfetamine sulphate and atomoxetine for attention deficit hyperactivity disorder (ADHD) in children and adolescents (commercial in confidence information removed). New York 2004.
105. National Institute for Health and Clinical Excellence (NICE). Final Appraisal Determination: Methylphenidate, atomoxetine and dexamfetamine for attention deficit hyperactivity disorder (ADHD) in children and adolescents. London: NICE 2005.
106. National Institute for Health and Clinical Excellence (NICE). Appraisal of methylphenidate, atomoxetine and dexamfetamine for attention deficit hyperactivity disorder in children and adolescents: Decision of the Panel. London: NICE 2005.
107. King S, Griffin S, Hodges Z, et al. A systematic review and economic model of the effectiveness and cost-effectiveness of methylphenidate, dexamfetamine and atomoxetine for the treatment of attention deficit hyperactivity disorder in children and adolescents. Health Technol Assess 2006; 10 (23): iii-iv, xiii-146.
108. Coghill D, Spender Q, Barton J, et al. Measuring quality of life in children with attention-deficit/hyperactivity disorder in the UK. 16th World Congress of the International Association for Child and Adolescent Psychiatry and Allied Professions (IACAPAP). Book of Abstracts. Darmstadt: Steinkopff-Verlag 2004; p. 327.
109. Sharp WS, Alter JM, Marsh WL, et al. ADHD in girls: clinical comparability of a research sample. J Am Acad Child Adolesc Psychiatry 1999; 38: 40-7.
110. Schlander M. The NICE ADHD health technology assessment: a review and critique. Child Adolesc Psychiatr Mental Health 2008; 2: 1: 1-9.
111. Rawlins MD, Culyer AJ. National institute of clinical excellence and its value judgments. Br Med J 2004; 329: 224-7.
112. National Institute for Clinical Excellence (NICE). Guide to the technology appraisal process (reference N0514). London: NICE 2004.
113. Capelleri JC, Ioannidis JP, Schmid CH, et al. Large trials versus meta-analysis of smaller trials: how do their results compare? J Am Med Assoc (JAMA) 1996; 276 (16): 1332-8.
114. Schachar R, Jadad AR, Gauld M, et al. Attention-deficit hyperactivity disorder: critical appraisal of extended treatment studies. Canadian J Psychiatry 2002; 47 (4): 337-48.
115. Shrier I, Platt RW, Steele RJ. Mega-trials vs. meta-analysis: precision vs. heterogeneity? Contemp Clin Trials 2007; 28 (3): 324-8.
116. Wells KC, Pelham WE, Kotkin RA, et al. Psychosocial treatment strategies in the MTA Study: rationale, methods, and critical issues in design and implementation. J Abnorm Child Psychol 2000; 28 (6): 483-505.
117. Wells KC. Comprehensive versus matched psychosocial treatment in the MTA Study: conceptual and empirical issues. J Clin Child Psychol 2001; 30 (1): 131-5.
118. Greenhill LL, Abikoff H, Arnold LE, et al. Medication treatment strategies in the MTA Study: relevance to clinicians and researchers. J Am Acad Child Adolesc Psychiatry 1996; 35 (10): 1304-13.
119. Greenhill LL, Swanson JM, Vitiello B, et al. Impairment and deportment responses to different methylphenidate doses in children with ADHD: the MTA titration trial. J Am Acad Child Adolesc Psychiatry 2001; 40 (2): 180-7.
120. Vitiello B, Severe JB, Greenhill LL, et al. Methylphenidate dosage for children with ADHD over time under controlled conditions: lessons from the MTA. J Am Acad Child Adolesc Psychiatry 2001; 40 (2): 188-96.
121. Owens EB, Hinshaw SP, Kraemer HC, et al. Which treatment for whom for ADHD? Moderators of treatment response in the MTA. J Consult Clin Psychol 2003; 71 (3): 540-52.
122. Swanson JM, Kraemer HC, Hinshaw SP, et al. Clinical relevance of the primary findings of the MTA: success rates based on severity of ADHD and ODD symptoms at the end of treatment. J Am Acad Child Adolesc Psychiatry 2001; 40 (2): 168-79
123. MTA Cooperative Group. National Institute of Mental Health Multimodal Treatment Study of ADHD follow-up: 24-month outcomes of treatment strategies for attention-deficit/hyperactivity disorder. Pediatrics 2004; 113 (4): 754-61.
124. Jensen PS, Arnold LE, Swanson JM, et al. 3-year- follow-up of the NIMH MTA Study. J Am Acad Child Adolesc Psychiatry 2007; 46 (8): 989-1002.
125. Molina BSG, Hinshaw SP, Swanson JM, et al. The MTA at 8 years: prospective follow-up of children treated for combined-type ADHD in a multisite study. J Am Acad Child Adolesc Psychiatry 2009, 48 (5): 484-500.
126. Swanson JM, Hinshaw SP, Arnold LE, et al. Secondary evaluations of MTA 36-month outcomes: propensity score and growth mixture model analyses. J Am Acad Child Adolesc Psychiatry 2007; 46 (8): 1003-14.
127. Molina BSG, Flory K, Hinshaw SP, et al. Delinquent behavior and emerging substance use in the MTA at 36 months: prevalence, course, and treatment effects. J Am Acad Child Adolesc Psychiatry 2007; 46 (8): 1028-40.
128. Banaschewski T, Buitelaar J, Coghill DR, et al. The MTA at 8. J Am Acad Child Adolesc Psychiatry 2009; 48 (11): 1120-2.
129. Pliszka SR. The MTA at 8. J Am Acad Child Adolesc Psychiatry 2009; 48 (11): 1122.
130. Molina BSG, Hinshaw SP, Swanson JM. Arno,ld LE, for the MTA Cooperative Group. The MTA at 8. J Am Acad Child Adolesc Psychiatry 2009; 48 (11): 1122-3.
131. Efron B, Tibshirani R. An introduction to the bootstrap. New York, NY: Chapham and Hall 1993.
132. Jensen PS, Garcia JA, Glied S, et al. Cost-effectiveness of ADHD treatments: findings from the multimodal treatment study of children with ADHD. Am J Psychiatry 2005; 162 (9): 1628-36.
133. Bird H, Shaffer D, Fisher P, et al. The Columbia impairment scale (CIS): pilot findings on a measure of global impairment for children and adolescents. Int J Methods Psychiatr Res 1993; 3: 167-76.
134. Bird HR, Andrews H, Schwab Stone M, et al. Global measures of impairment for epidemiological and clinical use with children and adolescents. Int J Methods Psychiatr Res 1996; 6 (4): 295-307.
135. Bird HR. Columbia Impairment Scale (CIS). In: American Psychiatric Association (APA). Handbook of Psychiatric Measures. Washington, DC: APA 2000; pp. 367-9.
136. Foster EM, Jensen PS, Schlander M, et al. Treatment for ADHD: is more complex treatment cost-effective for more complex cases? Health Serv Res 2007; 42 (1): 165-82.
137. Santosh PJ, Taylor E, Swanson J, et al. Refining the diagnoses of inattention and overactivity syndromes: a reanalysis of the Multimodal Treatment study of attention deficit hyperactivity disorder (ADHD) based on ICD-10 criteria for hyperkinetic disorder. Clin Neurosci Res 2005; 5: 307-14.
138. Schlander M, Jensen PS, Foster EM, et al. Incremental costeffectiveness ratios of clinically proven treatments for attentiondeficit/ hyperactivity disorder (ADHD): impact of diagnostic criteria and comorbidity. 5th World Congress, International Health Economics Association (iHEA). Book of Abstracts. Barcelona, Spain: UPF 2005; pp. 194-5.
139. Schlander M, Schwarz O, Trott GE, et al. Treatment of attentiondeficit/hyperactivity disorder (ADHD): are U.S. cost-effectiveness findings based upon the MTA Study relevant to mental health care policy makers in Germany? Value Health 2005; 8 (6): A197.
140. Schlander M, Schwarz O, Hakkaart-van Roijen L, et al. Achieving normalization of core symptoms: cost-effectiveness of ADHD treatment strategies in the international context. J Mental Health Policy Econ 2007; 10 (Suppl 1): S38.
141. Schlander M, Schwarz O, Hakkaart-van Roijen L, et al. Improving functional impairment in major life activities: cost-effectiveness of ADHD treatment strategies in the international context. J Mental Health Policy Econ 2007; 10 (Suppl 1): S38.
142. Schlander M, Schwarz O, Foster EM, et al. Cost-effectiveness of ADHD treatment strategies in the international context: impact of therapeutic objectives and comorbidity. J Mental Health Policy Econ 2007; 10 (Suppl 1): S37.
143. Klein RG, Abikoff HG, Hechtman L, et al. Design and rationale of controlled study of long-term methylphenidate and multimodal psychosocial treatment in children with ADHD. J Am Acad Child Adolesc Psychiatry 2004; 43 (7): 792-80.
144. Schlander M, Trott GE, Schwarz O. The health economics of attention deficit hyperactivity disorder in Germany. Part 2: therapeutic options and their cost effectiveness. Nervenarzt 2010; 81 (3): 301-14.
145. Marchetti A, Magar R, Lau H, et al. Pharmacotherapies for attention- deficit/hyperactivity disorder: expected cost analysis. Clin Therapeut 2001; 23 (11): 1904-21.
146. Narayan S, Hay J. Cost effectiveness of methylphenidate versus AMP/DEX mixed salts for the first-line treatment of ADHD. Expert Rev Pharmacoecon Outcomes Res 2004; 4 (6): 625-34.
147. Faraone SV, Biederman J, Roe C. Comparative efficacy of Adderall and methylphenidate in attention-deficit/hyperactivity disorder: a meta-analysis. J Clin PsychoPharmacol 2002; 22 (5): 468-73.
148. Faraone SV, Buitelaar J. Comparing the efficacy of stimulants for ADHD in children and adolescents using meta-analysis. Eur Child Adolesc Psychiatry 2010; 19 (4): 353-64.
149. Donnelly M, Haby MM, Carter R, et al. Cost-effectiveness of dexamphetamine and methylphenidate for the treatment of childhood attention deficit hyperactivity disorder. Aust N Z J Psychiatry 2004; 38 (8): 592-601.
150. Gold MR, Stevenson D, Fryback DG. HALYs and QALYs and DALYs, oh my: similarities and differences in summary measures of population health. Ann Rev Public Health 2002; 23: 115-34.
151. Stouthard MEA, Essink-Bot ML, Bonsel GJ, et al. Disability weights for diseases in the Netherlands. Rotterdam: Department of Public Health, Erasmus University 1997.
152. Landgraf JM, Rich M, Rappaport L. Measuring the quality of life in children with attention-deficit/hyperactivity disorder and their families: development and evaluation of a new tool. Arch Pediatr Adolesc Med 2002; 156 (4): 384-91.
153. Claxton A, Cramer J, Pierce C. A systematic review of the associations between dose regimens and medication compliance. Clin Therapeut 2001; 23 (8): 1296-310.
154. Wolraich ML, Greenhill LL, Pelham WL, et al. Randomized, controlled trial of OROS methylphenidate once a day in children with attention-deficit/hyperactivity disorder. Pediatrics 2001; 108 (4): 883-92.
155. Pelham WE, Gnagy EM, Borroughs-Maclean L, et al. Once-a-day Concerta methylphenidate versus three-times-daily methylphenidate in laboratory and natural settings. Pediatrics 2001; 107 (6): e105/1-15.
156. Swanson JM, Gupta S, Lam A, et al. Development of a new oncea- day formulation of methylphenidate for the treatment of attention-deficit/hyperactivity disorder: proof-of-concept and proof-ofproduct studies. Arch Gen Psychiatry 2003; 60 (2): 204-11.
157. Annemans L, Ingham M. Estimating cost-effectiveness of Concerta OROS in attention-deficit/hyperactivity disorder (ADHD) - adapting the Canadian Coordinating Office for Health Technology Assessment's (CCOHTA) economic model of methylphenidate immediate release versus behavioural interventions from a parent's perspective. Value Health 2000; 5 (6): 517.
158. Schlander M. Cost-effectiveness of methylphenidate OROS for attention-deficit/hyperactivity disorder (ADHD): an evaluation from the perspective of the UK National Health Service (NHS). Value Health 2004; 7 (3): 236.
159. Schlander M, Migliaccio-Walle K, Caro J. Treatment of attentiondeficit/ hyperactivity disorder (ADHD): modelling the costeffectiveness of a modified-release preparation of methylphenidate from the perspective of the National Health Service (NHS) in the United Kingdom (UK). 16th World Congress of the International Association for Child and Adolescent Psychiatry and Allied Professions (IACAPAP), Berlin, August 22-26, 2004. Book of Abstracts. Darmstadt: Steinkopff-Verlag: 2004; S-112-522: 189.
160. Schlander M, Trott GE, Migliaccio-Walle K, et al. Kosteneffektivität verbesserter Compliance mit medikamentöser Therapie der Aufmerksamkeitsdefizit-/Hyperaktivitätsstörung bei Kindern und Jugendlichen aus der Perspektive der Gesetzlichen Krankenversicherung. Annual Meeting, Berufsverband der Ärzte für Kinder- und Jugendpsychiatrie und Psychotherapie in Deutschland (BKJPP), Gelsenkirchen/Germany, November 11, 2004. Book of Abstracts. BKJPP-Jahrestagung 2004; p. 23.
161. Conners C. Conners' Rating Scales-Revised Technical Manual. North Tonawanda, NY: Multi-Health Systems 1997.
162. Conners CK. Conners' Rating Scales - Revised (CRS-R). In: American Psychiatric Association, Handbook of Psychiatric Measures. Washington, DC: APA 2000; pp. 329-32.
163. Hwang P, Cosby A, Laberge ME. Compliance with three-times daily methylphenidate in children with attention-deficit/ hyperactivity disorder. Value Health 2003; 6 (3): 273.
164. Lage M, Hwang P. Effects of methylphenidate formulation for attention deficit hyperactivity disorder on patterns and outcomes of treatment. J Child Adolesc PsychoPharmacol 2004; 14 (4): 575-81.
165. Marcus SC, Wan GJ, Kemner JE, et al. Continuity of methylphenidate treatment for attention-deficit/hyperactivity disorder. Arch Pediatr Adolesc Med 2005; 159: 572-8.
166. Sanchez RJ, Crismon ML, Barner JC, et al. Assessment of adherence measures with different stimulants among children and adolescents.
167. Kemner JE, Lage MJ. Effect of methylphenidate formulation on treatment patterns and use of emergency room services. Am J Health Syst Pharm 2006; 63 (4): 317-22.
168. Kemner JE, Lage MJ. Impact of methylphenidate formulation on treatment patterns and hospitalizations: a retrospective analysis. Ann Gen Psychiatry 2006; 5 (5): 1-8.
169. Schlander M. Long-acting medications for the hyperkinetic disorders: a note on cost-effectiveness. Eur Child Adolesc Psychiatry 2007; 16 (7): 421-9.
170. Ganapathy V, Hay JW. Cost-effectiveness of once-daily stimulant, nonstimulant & combined stimulant /behavioral therapy interventions in the treatment of ADHD in children. Value Health 2008; 11 (3): A117.
171. Devine JW, Tiller KW, Trice S, et al. Economic evaluation of long acting treatments for attention-deficit/hyperactivity disorder in the military health system. Value Health 2007; 10 (3): A78.
172. ®) vs. atomoxetine and shortacting methylphenidate for the managememt of attention deficit disorder with hyperactivity in Mexico. Value Health 2007; 10 (3): A74.
173. Faber A, van Agthoven M, Kalverdijk LJ, et al. Long-acting methylphenidate-OROS in youths with attention-deficit hyperactivity disorder suboptimally controlled with immediate-release methylphenidate - a study of cost effectiveness in The Netherlands. CNS Drugs 2008; 22 (2): 157-70.
174. Sonnenberg FA, Beck JR. Markov models in medical decision making: a practical guide. Med Decision Making 1993; 13 (4): 322-38.
175. Biederman J, Mick E, Faraone SV. Age-dependent decline of symptoms of attention deficit hyperactivity disorder: impact of remission definition and symptom type. Am J Psychiatry 2000; 157 (5): 816-8.
176. Faraone SV, Biederman J, Mick E. The age-dependent decline of attention deficit hyperactivity disorder: a meta-analysis of followup studies. Psychol Med 2006; 36: 159-65.
177. Steele M, Weiss M, Swanson J, et al. A randomized, controlled, effectiveness trial of OROS-methylphenidate compared to usual care with immediate-release-methylphenidate in attention-deficithyperactivity-disorder. Canadian J Clin Pharmacol 2006; 13 (1): e50-62.
178. Secnik K, Matza LS, Cottrell S, et al. Health state utilities for childhood attention-deficit/hyperactivity disorder based on parent preferences in the United Kingdom. Med Decision Making 2005; 25: 56-70.
179. Xiao X, Damaraju CV, Durkin M. Patterns of augmentation of extended-release stimulants for ADHD wih immediate-release stimulants in children and adolescents. Value Health 2009; 12 (3): A188-9.
180. Christensen LL, Sasané R, Hodgkins P, et al. Medication augmentation in patients with attention-deficit hyperactivity disorder. Poster presentation at the 2nd Biennial International Congress on ADHD. Vienna/Austria 2009.
181. Weinstein MC, Toy EL, Sandberg EA, et al. Modeling for health care and other policy decisions: uses, roles, and validity. Value Health 2001; 4 (5): 9-17.
182. Weinstein MC, O'Brien B, Hornberger J, et al. Principles of good practice for decision analytic modeling in health-care evaluation: report of the ISPOR Task Force on good research practices - modeling studies. Value Health 2003; 6 (1): 9-17.
183. Hack S, Chow B. Pediatric psychotropic medication compliance: a literature review and research-based suggestions for improving treatment compliance. J Child Adolesc PsychoPharmacol 2001; 11 (19): 59-67.
184. Swanson J. Compliance with stimulants for attention-deficit/hyperactivity disorder. Issues and approaches for improvement. CNS Drugs 2003; 17 (2): 117-31.
185. Baltussen R, Leidl R, Ament A. Real world designs in economic evaluation: bridging the gap between clinical research and policymaking. Pharmacoeconomics 1996; 16 (5): 449-58.
186. Revicki DA, Frank L. Pharmacoeconomic evaluations in the real world: effectiveness versus efficacy studies. Pharmacoeconomics 1999; 15 (5): 423-34.
187. Hughes DA, Bagust A, Haycox A, et al. Accounting for noncompliance in pharmacoeconomic evaluations. Pharmacoeconomics 2001; 19 (12): 1185-97.
188. March JS, Silva SG, Compton S, et al. The case for practical clinical trials in psychiatry. Am J Psychiatry 2005; 162 (5): 836-46.
189. Ramsey S, Willke R, Briggs A, et al. Good research practices for cost-effectiveness analysis alongside clinical trials: the ISPOR RCT-CEA Task Force report. Value Health 2005; 8 (5) 521-33.
190. Rothenberger A, Coghill D, Döpfner M, et al. Naturalistic observational studies in the framework of ADHD health care. Eur Child Adolesc Psychiatry 2006; 15 (Suppl. 1): I/1-I/3.
191. Schlander M, Hjelmgren J. Cost-effectiveness of long-acting methylphenidate for treatment of attention-deficit/hyperactivity disorder (ADHD) in children and adolescents in Finland: an evaluation based upon a randomized clinical trial (RCT). Value Health 2008; 11 (6): A339.
192. Steinhoff K. Attention-deficit/hyperactivity disorder: medication treatment-dosing and duration of action. Am J Manag Care 2004; 10 (4): S99-106.
193. Steinhoff K, Wigal T, Swanson J. Single daily dose ADHD medication effect size evaluation. Poster presentation. 50th Annual Meeting of the American Academy for Child and Adolescent Psychiatry, Miami, FL 2003.
194. Faraone SV. Understanding the effect size of ADHD medications: implications for clinical care. Medscape Psychiatr Mental Health 2003; 8: 1-7.
195. Faraone SV, Spender T, Aleardi M, et al. Comparing the efficacy of medications used for ADHD using meta-analysis. Program and abstracts of the 156th Annual Meeting of the American Psychiatric Association; San Francisco, CA 2003.
196. Faraone SV, Biederman J, Spencer TJ, et al. Comparing the efficacy of medications for ADHD using meta-analysis. Medscape Gen Med 2006; 8 (4): 4.
197. Kratochvil CJ, Heiligenstein FH, Dittmann R, et al. Atomoxetine and methylphenidate treatment in children with ADHD: a prospective, randomised, open-label trial. J Am Acad Child Adolesc Psychiatry 2002; 41: 776-84.
198. Kemner JE, Starr HL, Ciccone PE, et al. Outcomes of OROS methylphenidate compared with atomoxetine in children with ADHD: a multicenter, randomized prospective study. Adv Therapy 2005; 22 (5): 498-512.
199. Newcorn JH, Owens JA, Jasinski DR, et al. Results from recently completed comparator studies with atomoxetine and methylphenidate. 51st Annual Meeting of the American Academy of Child & Adolescent Psychiatry (AACAP), Washington, DC: Symposium 2004.
200. Newcorn J, Kratochvil CJ, Allen AJ, et al. Atomoxetine and OROS methylphenidate for the treatment of ADHD: acute results and methodological issues. Poster presentation at 45th Annual Meeting of the New Clinical Drug Evaluation Unit (NCDEU) of the National Institute of Mental Health (NIMH), Boca Raton, FL, June 6-9, 2005, Book of Abstracts 188.
201. Newcorn JH, Kratochvil CJ, Allen AJ, et al. Atomoxetine and osmotically released methylphenidate for the treatment of attention deficit hyperactivity disorder: acute comparison and differential response. Am J Psychiatry 2008; 165 (6): 721-30.
202. ®) in school-aged children with attention- deficit/hyperactivity disorder. J Attention Disord 2005; 9 (1): 275-89.
203. Wang Y, Zheng Y, Du Y, et al. Atomoxetine versus methylphenidate in paediatric outpatients with attention deficit hyperactivity disorder: a randomized, double-blind comparison trial. Austral N Z J Psychiatry 2007; 41: 222-30.
204. Iskedjian M, Maturi B, Walker JH, et al. Cost-effectiveness of atomoxetine in the treatment of attention deficit hyperactivity disorder in children and adolescents. Value Health 2003; 6 (3): 275.
205. Laing A, Cottrell S, Robinson P, et al. A modelled economic evaluation comparing atomoxetine with current therapies for the treatment of children with attention deficit/hyperactivity disorder (ADHD) in the Netherlands. Value Health 2005; 8 (6): A198.
206. Tilden D, Richardson R, Nyhus K, et al. A modelled economic evaluation of atomoxetine (Strattera) for the treatment of three patient groups with attention deficit hyperactivity disorder. Value Health 2005; 8 (6): A197.
207. Secnik K, Cottrell S, Matza LS, et al. Assessment of health state utilities for attention-deficit/hyperactivity disorder in children using parent-based standard gamble scores. Value Health 2004; 7 (3): 236.
208. Diamantopoulos A, Lorenzo M, Happich M, et al. A cost-utility analysis of atomoxetine against current stimulant therapies fir the treatment of children with attention-deficit/hyperactivity disorder (ADHD) in Germany. Value Health 2007; 10 (6): A298.
209. Cottrell S, Tilden D, Robinson P, et al. A modeled economic evaluation comparing atomoxetine with stimulant therapy in the treatment of children with attention-deficit/hyperactivity disorder in the United Kingdom. Value Health 2008; 11 (3): 376-88.
210. Prasad S, Arellano J, Steer C, et al. Assessing the value of atomoxetine in treating children and adolescents with ADHD in the UK. Int J Clin Pract 2009; 63 (7): 1031-40.
211. Hong J, Dilla T, Aranello J. A modelled economic evaluation comparing atomoxetine with methylphenidate in the treatment of children with attention-deficit/hyperactivity disorder in Spain. BMC Psychiatry 2009; 9 (15): 1-13.
212. Vitiello B. Improving decision making in the treatment of ADHD. Am J Psychiatry 2008; 165 (6): 666-7.
213. Arnold LE, Lindsay RL, López FA, et al. Treating attentiondeficit/hyperactivity disorder with a stimulant transdermal patch: the clinical art. Pediatrics 2007; 120 (5): 1100-6.
214. Najib J. The efficacy and safety profile of lisdexamfetamine dimesylate, a pro-drug of d-amphetamine, for the treatment of attentiondeficit/ hyperactivity disorder in children and adults. Clin Therapeut 2009; 31 (1): 142-76.
215. Haby MM, Carter R, Mihalopoulos C, et al. Assessing costeffectiveness - mental health: introduction to the study and methods. Aust N Z J Psychiatry 2004; 38 (8): 569-78.
216. Haby MM, Tonge B, Littlefield L, et al. Cost-effectiveness of cognitive behavioural therapy and selective serotonin reuptake inhibitors for major depression in children and adolescents. Aust N Z J Psychiatry 2004; 38 (8): 579-91.
217. Byford S, Barrett B, Roberts C, et al. Cost-effectiveness of selective serotonin reuptake inhibitors and routine specialist care with and without cognitive-behavioural therapy in adolescents with major depression. Br J Psychiatry 2007; 191 (12): 521-7.
218. Goodyer IM, Dubicka B, Wilkinson P, et al. A randomized controlled trial of cognitive behaviour therapy in adolescents with major depression treated by selective serotonin reuptake inhibitors. The ADAPT trial. Health Technol Assess 2008; 12 (14): iii-iv; ix-60.
219. Treatment for Adolescents with Depression Study Team. Treatment for Adolescents with Depression Study (TADS): rationale, design, and methods. J Am Acad Child Adolesc Psychiatry 2003; 42 (5): 531-42.
220. Domino ME, Burns BJ, Kratochvil CJ, et al. Cost-effectiveness of treatments for adolescent depression: results from TADS. Am J Psychiatry 2008; 165 (5): 588-96.
221. Domino ME, Foster EM, Vitiello B, et al. Relative costeffectiveness of treatments for adolescent depression: 36-week results from the TADS randomized trial. J Am Acad Child Adolesc Psychiatry 2009; 48 (7): 711-20.
222. March JS, Silva S, Petrycki S, et al. Fluoxetine, cognitivebehavioral therapy, and their combination for adolescents with depression: Treatment for Adolescents with Depression Study (TADS) randomized controlled trial. J Am Med Assoc (JAMA) 2004; 292 (7): 807-20.
223. Pyne JM, Tripathi S, Williams DK, et al. Depression-free day to utility-weighted score: is it valid? Medical Care 2007; 45: 357-62.
224. March JS, Silva S, Petrycki S, et al. The Treatment for Adolescents with Depression Study (TADS): long-term effectiveness and safety outcomes. Arch Gen Psychiatry 2007; 64: 1132-43.
225. Heuzenroeder L, Donnelly M, Haby MM, et al. Cost-effectiveness of psychological and pharmacological interventions for generalized anxiety disorder and panic disorder. Aust N Z J Psychiatry 2004; 38 (8): 602-12.
226. Mahe V, Balogh A. Long-term pharmacological treatment of generalized anxiety disorder. Int Clin PsychoPharmacol 2000; 15 (2): 99-105.
227. Otto MW, Pollack MH, Maki KM. Empirically supported treatments for panic disorder: costs, benefits, and stepped care. J Consulting. Clin Psychol 2000; 68 (4): 556-63.
228. De Civita M, Regier D, Alamgir AH, et al. Evaluating healthrelated quality-of-life studies in paediatric populations: some conceptual, methodological and developmental considerations and recent applications. Pharmacoeconomics 2005; 23 (7): 659-85.
229. Griebsch I, Coast J, Brown J. Quality-adjusted life-years lack quality in pediatric care: a critical review of published cost-utility studies in child health. Pediatrics 2005; 115: e600-e614.
230. Danckaerts M, Sonuga-Barke EJ, Banaschewski T, et al. The quality of life of children with attention-deficit/hyperactivity disorder: a systematic review. Eur Child Adolesc Psychiatry 2010; 19: 83-105.
231. Dworkin R. Taking rights seriously. Cambridge: Harvard University Press 1977.
232. Richardson J, McKie J. Empiricism, ethics and orthodox economic theory: what is the appropriate basis for decision-making in the health sector? Soc Sci Med 2005; 60: 265-75.
233. Schlander M. Kosteneffektivität und Ressourcenallokation: Gibt es einen normativen Anspruch der Gesundheitsökonomie? In: Kick HA, Taupitz J, Eds. Gesundheitswesen zwischen Wirtschaftlichkeit und Menschlichkeit. Muenster: LIT-Verlag 2005; pp. 37-112.
234. Richardson J, McKie J. Economic evaluation of services for a National health scheme: the case for a fairness-based framework. J Health Econ 2007; 26 (4): 785-99.
235. Chisholm D. Keeping pace with Assessing Cost-Effectiveness: economic efficiency and priority-setting in mental health. Aust N Z J Psychiatry 2005; 39: 645-7.
236. Schwartz D, Lellouch J. Explanatory and pragmatic attitudes in therapeutic trials. J Chron Dis 1967; 20: 637-48
237. Reeves G, Anthony B. Multimodal treatments versus pharmacotherapy alone in children with psychiatric disorders - implications of access, effectiveness, and contextual treatment. Pediatr Drugs 2009; 11 (3): 165-9
238. Baker CB, Johnsrud MT, Crismon ML, et al. Quantitative analysis of sponsorship bias in economic studies of antidepressants. Br J Psychiatry 2003; 183: 498-506.
239. Timimi S. Child psychiatry and its relationship the pharmaceutical industry: theoretical and practical issues. Adv Psychiatr Treat 2008; 14: 3-9.
240. James A. Pharmacotherapy and child psychiatry: is there a way forward? Adv Psychiatr Treat 2008; 14: 10-16.
241. Schlander M. The contribution of health economics to marketoriented pharmaceutical research and development. Witten/Germany: Universität Witten-Herdecke Verlagsgesellschaft 1998.
242. Avorn J. The role of pharmacoepidemiology and pharmacoeconomics in promoting access and stimulating innovation. PharmacoEconomics 2004; 22 (Suppl 2): 81-6.
243. Vitiello B. Recent developments and strategies in pediatric pharmacology research in the USA. Child Adolesc Psychiatr Mental Health 2008; 2: 36, 1-5.
244. Upudhyaya HP, Gault L, Allen AJ. Challenges and opportunities in bringing new medications to market for pediatric patients. J Am Acad Child Adolesc Psychiatry 2009; 48 (11): 1056-959.
245. Baldwin DS. Room for improvement in the pharmacological treatment of anxiety disorders. Curr Pharm Des 2008; 14(33): 3482-3491.
246. Berenguer B, La CC, de la Matta MJ, Martin-Calero MJ. Pharmaceutical care: past, present and future. Curr Pharm Des 2004; 10(31): 3931-3946.
247. Workman P. How much gets there and what does it do?: The need for better pharmacokinetic and pharmacodynamic endpoints in contemporary drug discovery and development. Curr Pharm Des 2003; 9(11): 891-902.